Key result
Generic BP meds provide far greater cost-effectiveness than brand-name drugs at ~$8,000 per QALY.
Answers are grounded in this paper and cite their sources.
In this article we highlight the important role that medication therapy can play in preventing disease and controlling costs. Focusing on coronary artery disease, we demonstrate that prevention, with the appropriate use of generic medications, appears far more cost-effective than previously documented, and it may even save on costs. For example, an earlier study estimated that reducing blood pressure to widely established clinical guidelines in nondiabetic patients cost an estimated $52,983 per quality-adjusted life-year if a brand-name drug was used. However, we estimate that the cost is just $7,753 per quality-adjusted life-year at generic medication prices. As the nation attempts to find strategies to improve population health without adding to the unsustainably high cost of care, policy makers should focus on ensuring that patients have access to essential generic medications.
No takes yet. Share an insight, caveat, or question.
Shrank et al. (2011) studied Coronary artery disease and hypertension. Generic medications for disease prevention vs. Brand-name medications was evaluated on Cost per quality-adjusted life-year (QALY) for blood pressure reduction. Generic medications for blood pressure reduction in nondiabetic patients cost an estimated $7,753 per QALY compared to $52,983 per QALY for brand-name drugs.
Synapse has enriched 10 related papers. Consider them for comparative context: